| Literature DB >> 36013211 |
Vladimir B Berikov1,2, Olga A Kutnenko2, Julia F Semenova1, Vadim V Klimontov1.
Abstract
Nocturnal hypoglycemia (NH) is a dangerous complication of insulin therapy that often goes undetected. In this study, we aimed to generate machine learning (ML)-based models for short-term NH prediction in hospitalized patients with type 1 diabetes (T1D). The models were trained on continuous glucose monitoring (CGM) data obtained from 406 adult patients admitted to a tertiary referral hospital. Eight CGM-derived metrics of glycemic control and glucose variability were included in the models. Combinations of CGM and clinical data (23 parameters) were also assessed. Random Forest (RF), Logistic Linear Regression with Lasso regularization, and Artificial Neuron Networks algorithms were applied. In our models, RF provided the best prediction accuracy with 15 min and 30 min prediction horizons. The addition of clinical parameters slightly improved the prediction accuracy of most models, whereas oversampling and undersampling procedures did not have significant effects. The areas under the curve of the best models based on CGM and clinical data with 15 min and 30 min prediction horizons were 0.97 and 0.942, respectively. Basal insulin dose, diabetes duration, proteinuria, and HbA1c were the most important clinical predictors of NH assessed by RF. In conclusion, ML is a promising approach to personalized prediction of NH in hospitalized patients with T1D.Entities:
Keywords: artificial neuron networks; continuous glucose monitoring; hypoglycemia; machine learning; prediction; random forest; type 1 diabetes
Year: 2022 PMID: 36013211 PMCID: PMC9409948 DOI: 10.3390/jpm12081262
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
CGM-derived metrics used for the engineering of ML models.
| Parameter | Formula |
|---|---|
| CV |
|
| LI |
|
| LBGI | |
| CONGA-1 |
|
| Minimum value |
|
| DLV |
|
| ALV |
|
| LC |
|
Abbreviations: ALV, acceleration over the last values; CONGA-1, 1-h continuous overlapping net glycemic action; CV, coefficient of variation; DLV, difference between the last two values; LBGI, low blood glucose index; LC, linear trend coefficient; LI, lability index.
Clinical characteristics of T1D patients.
| General Demographic and Clinical Parameters | |
|---|---|
| Sex, m/f, | 147/259 (36.2/63.8) |
| Age, years | 36 (28–48) |
| BMI, kg/m2 | 23.6 (21.2–27.1) |
| Waist-to-hip ratio | 0.84 (0.78–0.91) |
| Current smoking, | 68 (16.7) |
|
| |
| Diabetes duration, years | 16 (10–25) |
| Daily insulin dose, IU | 40 (29.1–53.6) |
| Daily insulin dose, IU/kg | 0.59 (0.47–0.76) |
| Daily basal insulin dose, IU | 19.0 (13.6–26) |
| Daily basal insulin dose, IU/kg | 0.28 (0.21–0.38) |
| Diabetic retinopathy, | 246 (60.6) |
| Chronic kidney disease, | 274 (67.5) |
| Neuropathy, | 301 (74.1) |
| Impaired awareness of hypoglycemia, | 148 (36.5) |
| Arterial hypertension, | 159 (39.2) |
| Coronary artery disease, | 31 (7.6) |
|
| |
| HbA1c, % | 8.1 (7.1–9.2) |
| Total cholesterol, mmol/L | 5.0 (4.2–5.9) |
| LDL cholesterol, mmol/L | 3.0 (2.4–3.7) |
| HDL cholesterol, mmol/L | 1.5 (1.3–1.7) |
| Triglycerides, mmol/L | 1.0 (0.7–1.4) |
| Serum creatinine, µmol/L | 81.9 (73.7–94.0) |
| eGFR, mL/min/1.73 m2 | 88.0 (73.0–100.0) |
| UACR, mg/mmoL | 2.1 (2.0–7.65) |
Continuous data are presented as medians (25th–75th percentiles). Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; T1D, type 1 diabetes; UACR, urinary albumin-to-creatinine ratio.
Quality metrics (%) of the ML models for NH prediction.
| PH | Sampling/Parameters | RF | LogRLasso | ANN | ||||
|---|---|---|---|---|---|---|---|---|
| CGM | CGM + Clinical Data | CGM | CGM + Clinical Data | CGM | CGM + Clinical Data | |||
|
|
|
| 93.6 (3.4) | 90.9 (2.8) | 93.6 (1.9) | 93.0 (3.0) | 90.5 (5.9) | 90.8 (2.5) |
|
|
| 91.8 (1.2) | 94.5 (2.6) | 93.6 (3.4) | 92.4 (2.5) | 88.6 (3.6) | 90.3 (3.1) | |
|
|
| 88.2 (5.2) | 92.3 (3.4) | 90.5 (6.7) | 90.8 (4.7) | 90.0 (4.7) | 91.9 (3.7) | |
|
|
|
| 87.6 (1.9) | 86.6 (3.6) | 90.4 (1.7) | 91.0 (3.5) | 87.6 (3.9) | 84.6 (5.2) |
|
|
| 87.1 (4.6) | 90.4 (4.7) | 87.1 (4.0) | 86.9 (4.0) | 86.6 (3.2) | 83.3 (4.2) | |
|
|
| 89.5 (3.6) | 92.4 (3.1) | 85.1 (5.6) | 90.3 (3.2) | 85.1 (5.3) | 85.2 (3.6) | |
The SD values of the estimates obtained with cross-validation process are shown in the parentheses. The highest AUC values for each PH and ML algorithm are highlighted in bold. Abbreviations: ANN, Artificial Neural Networks; AUC, area under the curve; CGM, continuous glucose monitoring; LogRLasso, Logistic Linear Regression with Lasso regularization; NP, nocturnal hypoglycemia; PH, prediction horizon; RF, Random Forest; OS, oversampling; NS, no sampling; US, undersampling; Se, sensitivity; Sp, specificity.
The most important NH predictors revealed by RF in patients with T1D.
| PH | Parameters | Importance | Effect |
|---|---|---|---|
| 15 min | Minimal glucose | 1.000 | − |
| LBGI | 0.786 | + | |
| DLV | 0.723 | + | |
| CONGA-1 | 0.625 | + | |
| LC | 0.542 | − | |
| Proteinuria | 0.494 | + | |
| Basal insulin dose, IU/kg | 0.488 | + | |
| Diabetes duration | 0.457 | + | |
| Autonomic neuropathy | 0.383 | + | |
| HbA1c | 0.379 | − | |
| 30 min | Minimal glucose | 1.000 | − |
| LBGI | 0.845 | + | |
| Daily insulin dose, IU/kg | 0.770 | + | |
| HbA1c | 0.698 | − | |
| Diabetes duration | 0.693 | + | |
| Basal insulin dose, IU/kg | 0.666 | + | |
| Proteinuria | 0.653 | + | |
| eGFR | 0.652 | + | |
| DLV | 0.589 | + | |
| BMI | 0.577 | − |
Effect: the risk of NH increases as the parameter value increases (+); the risk of NH decreases as the parameter value increases (−). Abbreviations: BMI, body mass index; CONGA-1, 1 h continuous overlapping net glycemic action; DLV, difference between the last two values; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin A1c; LBGI, Low Blood Glucose Index; LC, linear trend coefficient; NH, nocturnal hypoglycemia; RF, Random Forest; T1D, type 1 diabetes.